Despite huge progress in the surgical management of ischemic mitral regurgitation, there is still controversy regarding the ideal treatment option.
Our study aimed to define an algorithmic approach in order to select those patients who will benefit the most from concomitant mitral valve procedure.
Patients with mitral regurgitation (MR) who met the inclusion criteria were included in our study. Patients with structural MR including ruptured chordae or papillary muscle, abnormal leaflet thickening, annular calcification, or other valvular or congenital heart diseases, ventricular aneurysms and those who were candidates for other surgical procedures were excluded. A total of 350 patients (about 12 %) were classified as having ischemic mitral regurgitation (IMR) and were enrolled in our analysis. All the patients underwent coronary artery bypass grafting and by the designed algorithmic approach were also decided to have additive procedures for their concomitant IMR.
Six months survival was 91.5 % among all the patients in this study. During the follow-ups 86.9 % of the patients survived . Overall mortality rate was 13.1 % (n = 46), of which 7.1 % (n = 25) occurred due to cardiac and 6 % (n = 21) as a result of a non-cardiac cause.
Individualising methods to select patients suffering from IMR for concomitant mitral valve procedure and coronary artery bypass grafting (CABG) seems to serves more effectively by reducing unnecessary surgeries and at the same time not missing absolute indications for concomitant valve repairs. Our algorithm showed a promising efficacy to effectively select patients for CABG and concomitant mitral valve procedures.